

## Deep brain stimulation in Huntington's disease.

Roberta Bonomo, MD,<sup>1,2\*</sup> Antonio E. Elia, MD, PhD,<sup>1\*</sup> Giulio Bonomo, MD,<sup>3</sup> Luigi M. Romito, MD, PhD,<sup>1</sup> Caterina Mariotti, MD,<sup>4</sup> Grazia Devigili, MD,<sup>1</sup> Roberto Cilia, MD,<sup>1</sup> Riccardo Giossi, MD,<sup>5,6</sup> Roberto Eleopra, MD<sup>1</sup>

<sup>1</sup>Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Milan, Italy; <sup>2</sup>Experimental Neurology Unit, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; <sup>3</sup>Fondazione IRCCS Istituto Neurologico Carlo Besta, Neurosurgery Department, Milan, Italy; <sup>4</sup>Unit of Medical Genetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; <sup>5</sup>Fondazione IRCCS. Istituto Neurologico Carlo Besta, Neuroimmunology and Neuromuscular Diseases Unit, Milan, Italy; <sup>6</sup>Department of Oncology and Onco-hematology, Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, Milan, Italy.

\* These authors have contributed equally to this work and share first authorship.

### Abstract (248/250)

**Background and aims:** Huntington's disease (HD) is a hereditary, progressive, neurodegenerative disorder with heterogeneous symptoms ranging from motor deterioration to cognitive decline. The complex constellation of the clinical manifestations still makes the therapeutic management challenging. In the new era of functional neurosurgery, deep brain stimulation (DBS) targeting the basal ganglia is emerging as a promising therapeutic approach in selected HD patients.

**Methods:** Articles describing the effect of DBS in patients affected by HD were selected from Medline and PubMed by the association of text words with MeSH terms as follows: "Deep brain stimulation", "DBS", and "HD", "Huntington's disease", "Huntington". Details on repeat expansion, age at operation, target of operation, duration of follow-up, stimulation parameters, adverse events, and outcome measures were collected.

**Results:** Twenty eligible studies, assessing 42 patients with HD, were identified. The effect of GPi-DBS on Unified Huntington's Disease Rating Scale (UHDRS) total score revealed in 10 studies an improvement of total score from 5.4% to 34.5%, and in 4 studies an increase of motor score from

3.8% to 97.8%. Bilateral GPi-DBS was reported to be effective in reduction of Chorea subscore in all studies, with a mean percentage reduction of 21.4% to 73.6%.

**Conclusions:** Chorea-dominant HD patients may be the best candidates for surgery, but the role of other clinical features and of disease progression should be elucidated. For this reason, there is a need for more reliable criteria that may drive the selection of HD patients suitable for DBS, accordingly further studies which have functional outcomes as primary endpoint are needed.